{"id":9632,"date":"2004-07-29T01:05:05","date_gmt":"2004-07-29T01:05:05","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=9632"},"modified":"2014-05-22T16:53:40","modified_gmt":"2014-05-22T16:53:40","slug":"no-evidence-for-cross-resistance-between-nevirapine-and-d4t","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/9632","title":{"rendered":"No evidence for cross resistance between nevirapine and d4T"},"content":{"rendered":"<p><strong>Simon Collins, HIV i-Base<\/strong><\/p>\n<p><strong>Two articles published last year (Blanca et al JBC 2003, Baldanti et al AIDS 2003) reported that resistance to d4T (stavudine) was related to the nevirapine-associated Y181C mutation. This included a report that Y181C\/I should eight fold resistance to d4T in a recombinant virus assay.<\/strong><\/p>\n<p>Prompted by the important implications of such cross-resistance on current interpretation systems for resistance reports Klaus Korn from the University of Erlangen-Nuremberg looked for corroborative evidence from a database of 500 RT genotype samples and corresponding phenotypic data to d4T.<\/p>\n<p>427\/511 samples without Y181C showed a median resistance factor for d4T of 1.8 (IQR 1.0-2.9). The 84\/511 samples with Y181C had a corresponding resistance factor of 2.7 (IQR 1.3-5.4). However this difference was explained by strong linked to RTI mutations in the same sequences. The 3\/84 samples without RTI resistance had resistance factors of 1.0, 1.1 and 1.4. Similarly only 16\/59 samples with phenotypic resistance to d4T &gt; 8-fold had Y181C.<\/p>\n<p>The study therefore failed to find an association between Y181C and d4T sensitivity and concluded that d4T should not be avoided as a treatment option on the basis of this genotypic mutation.<\/p>\n<p>Reference:<\/p>\n<p>Korn K, Schmidt B, Walter H. No evidence for stavudine resistance due to nevirapine-selected mutation Y181C in HIV-1 reverse transcriptase in a large genotype\/phenotype database. XIII Intl HIV Drug Resistance Workshop, 2004.\u00a0Abstract 43. Antiviral Therapy 2004; 9:S49.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Simon Collins, HIV i-Base Two articles published last year (Blanca et al JBC 2003, Baldanti et al AIDS 2003) reported that resistance to d4T (stavudine) was related to the nevirapine-associated Y181C mutation. This included a report that Y181C\/I should eight &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,36],"tags":[110],"class_list":["post-9632","post","type-post","status-publish","format-standard","hentry","category-conference-reports","category-drug-resistance","tag-idrw-13th-2004"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/9632","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=9632"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/9632\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=9632"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=9632"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=9632"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}